RECRUITING

320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.

Conditions

Atrial Fibrillation catheter ablation ECV Prognosis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment strategies.

Official Title

320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.

Quick Facts

Study Start:2025-03-04

Study Completion:2025-04-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06308094

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients must be at least 21 years old at the time of enrollment. * Patients must be able to give informed consent. * Patients with symptomatic paroxysmal/persistent atrial fibrillation (AF). * Eligible patients must be determined to be suitable candidates for ablation to treat AF by their cardiologist and/or electrophysiologists regardless of this protocol. * Patients are scheduled to have a pre-procedure cardiac CT upon the discretion of their electrophysiologists	* Known allergy to iodinated contrast media. * Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula). * Patients with a positive urine or serum pregnancy test will be excluded from this study. * Patients with heart transplantation. * Patients with polymorphic ventricular tachycardia (VT) or presenting in electrical storm. * Presence of any other history or condition that the investigator feels would be problematic. * Patient with iodinated contrast administration for other reason 24 hours prior to investigational CT. * Patients who have a heart pacemaker, metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, mechanical heart valves and prosthetics that contain metal. * Patients with severe claustrophobia.

Inclusion Criteria

Exclusion Criteria

* Patients must be at least 21 years old at the time of enrollment.
* Patients must be able to give informed consent.
* Patients with symptomatic paroxysmal/persistent atrial fibrillation (AF).
* Eligible patients must be determined to be suitable candidates for ablation to treat AF by their cardiologist and/or electrophysiologists regardless of this protocol.
* Patients are scheduled to have a pre-procedure cardiac CT upon the discretion of their electrophysiologists

* Known allergy to iodinated contrast media.
* Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula).
* Patients with a positive urine or serum pregnancy test will be excluded from this study.
* Patients with heart transplantation.
* Patients with polymorphic ventricular tachycardia (VT) or presenting in electrical storm.
* Presence of any other history or condition that the investigator feels would be problematic.
* Patient with iodinated contrast administration for other reason 24 hours prior to investigational CT.
* Patients who have a heart pacemaker, metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, mechanical heart valves and prosthetics that contain metal.
* Patients with severe claustrophobia.

Contacts and Locations

Study Contact

Konstantinos Aronis, MD PHD

CONTACT

2017169226

karonis1@jhmi.edu

Principal Investigator

Konstantinos Aronis, MD, PhD

PRINCIPAL_INVESTIGATOR

Johns Hopkins School of Medicine

Study Locations (Sites)

Johns Hopkins Hospital

Baltimore, Maryland, 21287

United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

Konstantinos Aronis, MD, PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-04

Study Completion Date2025-04-01

Study Record Updates

Study Start Date2025-03-04

Study Completion Date2025-04-01

Terms related to this study

Keywords Provided by Researchers

catheter ablation
ECV
Prognosis

Additional Relevant MeSH Terms

Atrial Fibrillation